Page 4 - Small Pharma News Today

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR ...

- Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space - - With the recently announced definitive agreement to acquire Small Pharma...

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE:CYBN) and UK-ba...

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

- Newly granted U.S. patent further strengthens the Company's leadership position in the deuterated tryptamine space - - With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately $60 (CA$80) million.

This collaboration aims to create a sector-leading organization with a substantial IP portfolio, including granted and pending patents.

Silo Wellness SILFF has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group NUGL in an arms-length transaction…

BioPharma Stock News - Cybin (NYSE American: CYBN) (NEO: CYBN) to Acquire Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF)

By Chris Wack Cybin is buying Small Pharma, a U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental health conditions,...